Toggle light / dark theme

Get the latest international news and world events from around the world.

Log in for authorized contributors

Could planets that orbit other stars be nonspherical?

Rich Livitski Seal Beach, California

Bodies large enough to be considered planets have enough mass that gravity molds them into a roughly spherical shape.

The key word here is roughly — other factors also come into play, such as a planet’s composition (rocky or gassy) and its rate of spin. The faster a planet spins, the more its rotation causes it to bulge outward at the equator. That’s because as a planet rotates, there’s a tug-of-war between the way material wants to fly off the planet due to rotation and the way gravity wants to pull all that planet’s material inward. The battle between these forces is most intense at the equator.

EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation

The two essential requirements for pathologic specimens in the era of personalized therapies for non-small cell lung carcinoma (NSCLC) are accurate subtyping as adenocarcinoma (ADC) versus squamous cell carcinoma (SqCC) and suitability for EGFR molecular testing, as well as for testing of other oncogenes such as EML4-ALK and KRAS. Actually, the value of EGFR expressed in patients with NSCLC in predicting a benefit in terms of survival from treatment with an epidermal growth factor receptor targeted therapy is still in debate, while there is a convincing evidence on the predictive role of the EGFR mutational status with regard to the response to tyrosine kinase inhibitors (TKIs).

This is a literature overview on the state-of-the-art of EGFR oncogenic mutation in NSCLC. It is designed to highlight the preclinical rationale driving the molecular footprint assessment, the progressive development of a specific pharmacological treatment and the best method to identify those NSCLC who would most likely benefit from treatment with EGFR-targeted therapy. This is supported by the belief that a rationale for the prioritization of specific regimens based on patient-tailored therapy could be closer than commonly expected.

Pulsed radiation therapy for the treatment of newly diagnosed glioblastoma

The results of this prospective study demonstrate the feasibility and safety of PRT for the treatment of newly diagnosed GBM patients. To our knowledge, this is the first study to investigate the use of PRT prospectively and in the definitive management of this patient population. The observed clinical outcomes are promising and compare favorably with those of well-matched patients treated at our institution with SRT as well as to historic controls. The 4 largest randomized trials investigating various treatments for newly diagnosed GBM reported median PFS of 4 to 7.3 months and mOS of 14.6 to 16.1 months in patients receiving concurrent SRT and TMZ, compared with 10.7 and 20.9 months for patients receiving PRT and TMZ on our study.,,, Notably, the patient cohort in our study has a slightly higher median age and a higher percentage of patients with subtotal tumor resection compared with all of the aforementioned trials.

All but one of the patients in this study had IDH–WT tumors, and only 3 patients had MGMT methylated tumors. These tumor characteristics portend a poor prognosis. The reported mOS in patients with IDH–WT tumors is in the range of 12 to 15 months., In a recent randomized trial, which investigated the addition of TTF to maintenance TMZ, patients with MGMT unmethylated tumors receiving SRT and TMZ had mOS of 14.7 months. Even the addition of TTF, which has resulted in the highest mOS in GBM patients reported by any major randomized trial to date, did not drastically improve survival in patients with MGMT unmethylated tumors (mOS of 16.9 mo).

Maintenance of QoL and preservation of NCF are important endpoints of treatment, especially in patients with GBM given their poor prognosis and relatively short life span. There are a paucity of longitudinal data on QoL and NCF after definitive treatment in GBM patients. Nonetheless, the existing evidence shows NCF to be an independent predictor of survival in high-grade gliomas and has a strong direct correlation with QoL and the ability to maintain independence and perform daily living activities.29–32 There has been a concerted effort to minimize RT-related NCF, and recent studies have shown promising results in this regard with the addition of memantine and employment of RT techniques that deliberately avoid the hippocampus, which is central to preservation of NCF.33,34 Unfortunately, cognitive decline remains a common complication in long-term GBM survivors.

EWSR1::FLI1 promotes neocentromere formation in ewing sarcoma cells

Kitagawa et al. show that in Ewing sarcoma, the EWSR1::FLI1 fusion protein recruits CENP-A to specific genomic sites where neocentromeres frequently assemble. The resulting dicentric chromosomes generate chromosome bridges, revealing a mechanism underlying the chromosomal instability that drives this cancer.

ProMUSE: Progressive Multimodal Uncertainty-Guided Staged Evidential Alzheimer Disease Classification

Alzheimer’s disease (AD) is a fatal disorder that destroys memory and cognitive skills in the elderly population. Treatments for AD are most effective in the early stage, leading to an increasing demand for early AD diagnosis increasingly relies on multimodal data, such as clinical assessments, structural magnetic resonance imaging (MRI), and positron emission tomography (PET) imaging. However, MRI and PET acquisition remain costly and not universally accessible, making all-modality inference impractical in real-world clinical workflows. We propose a progressive multimodal uncertainty-guided staged evidential network (ProMUSE) that adaptively determines when additional modalities are necessary. This helps reduce the overall cost of data acquisition while maintaining accuracy.

Phagocytic Function Analyses of GABBR-Related Microglia in Immature Developing Epileptic Brain Based on 10× Single-Nucleus RNA Sequencing Technology

Background: Epilepsy is a neurological disorder defined by the occurrence of epileptic seizures, which can significantly affect children, often leading to learning and cognitive impairments. Microglia, the resident immune cells of the central nervous system, are essential in clearing damaged neurons through phagocytosis. Notably, GABBR-associated microglia have been implicated in regulating phagocytic activity. Since the phagocytic function of microglia is critical in the pathogenesis of epilepsy, this study aims to investigate the role of GABBR-associated microglia in the development of the immature brain following epileptic seizures. Methods: Epilepsy was induced in a mouse model by the intraperitoneal injection of KA. Changes in the expression of the GABBR-related gene, GABBR2, in hippocampal microglia were analyzed using single-nucleus RNA sequencing (snRNA-seq). Cognitive and emotional changes in the mice were assessed through behavioral analyses. The expression of GABBR2 was semi-quantitatively measured using Western blotting, quantitative reverse transcription PCR, and immunofluorescence. Additionally, the spatial relationship between GABBR2 and hippocampal neurons was evaluated using Imaris software. Results: The snRNA-seq analysis revealed that GABBR2 expression was elevated in activated microglia in the hippocampus during chronic epilepsy compared to the early phase of seizures. Behavioral assessments demonstrated heightened anxiety levels and learning and memory impairments in the chronic epilepsy group compared to the control group. GABBR2 expression was upregulated in chronic epilepsy. Three-dimensional reconstruction analyses revealed a significantly increased contact volume between GABBR-associated microglia and neurons in the chronic epilepsy group compared to the control group. Conclusions: GABBR-associated microglia significantly contribute to the progression of immature brain diseases by promoting neuronal phagocytic activity.